

RhoA/Rho kinase mediates neuronal death through regulating cPLA₂ activation

Xiangbing Wu^{1,2,3,4}, Chandler L. Walker^{1,2,3,4}, Qingbo Lu^{1,3,4}, Wei Wu^{1,3,4}, Daniel B. Eddelman⁴, Jonathan M. Parish⁴ and Xiao-Ming Xu^{1,2,3,4}

¹Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, ²Department of Anatomy & Cell Biology, ³Department of Neurological Surgery, ⁴Goodman Campbell Brain and Spine, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA

*Corresponding author:

Xiao-Ming Xu, Ph.D.
Professor and Scientific Director
Spinal Cord and Brain Injury Research Group
Stark Neurosciences Research Institute
Indiana University School of Medicine
320 W. 15th Street, NB 500E
Indianapolis, IN 46202
Tel: (317) 274-1036
E-mail: xu26@iupui.edu

This is the author's manuscript of the article published in final edited form as:

Wu, X., Walker, C. L., Lu, Q., Wu, W., Eddelman, D. B., Parish, J. M., & Xu, X.-M. (2016). RhoA/Rho Kinase Mediates Neuronal Death Through Regulating cPLA₂ Activation. *Molecular Neurobiology*, 1–11.
<https://doi.org/10.1007/s12035-016-0187-6>

Abstract

Activation of RhoA/Rho kinase leads to growth cone collapse and neurite retraction. Although RhoA/Rho kinase inhibition has been shown to improve axon regeneration, remyelination and functional recovery, its role in neuronal cell death remains unclear. To determine whether RhoA/Rho kinase played a role in neuronal death after injury, we investigated the relationship between RhoA/Rho kinase and cytosolic phospholipase A₂ (cPLA₂), a lipase that mediates inflammation and cell death, using an *in vitro* neuronal death model and an *in vivo* contusive spinal cord injury model performed at the 10th thoracic (T10) vertebral level. We found that co-administration of TNF- α and glutamate induced spinal neuron death, and activation of RhoA, Rho kinase and cPLA₂. Inhibition of RhoA, Rho kinase and cPLA₂ significantly reduced TNF- α /glutamate-induced cell death by 33%, 52% and 43%, respectively ($p < 0.001$). Inhibition of RhoA and Rho kinase also significantly down-regulated cPLA₂ activation by 66% and 60%, respectively ($p < 0.01$). Furthermore, inhibition of RhoA and Rho kinase reduced the release of arachidonic acid, a downstream substrate of cPLA₂. The immunofluorescence staining showed that ROCK₁ or ROCK₂, two isoforms of Rho kinase, was co-localized with cPLA₂ in neuronal cytoplasm. Interestingly, co-immunoprecipitation (Co-IP) assay showed that ROCK₁ or ROCK₂, bonded directly with cPLA₂ and phospho-cPLA₂. When the Rho kinase inhibitor Y27632 was applied in mice with T10 contusion injury, it significantly decreased cPLA₂ activation and expression, and reduced injury-induced apoptosis in the lesion area. Taken together, our results reveal a novel mechanism of RhoA/Rho kinase-mediated neuronal death through regulating cPLA₂ activation.

Keywords: RhoA; Rho kinase; cytosolic phospholipase A₂; cell death; neuroprotection; spinal cord injury.

Introduction

A spinal cord injury (SCI) refers to any damage to the spinal cord that is caused by a trauma instead of disease [1]. SCI includes a primary mechanic injury followed by a much more complicated secondary injury process involving inflammation, oxidation and excitotoxicity [1]. Both injuries inevitably cause neuronal and glial cell death at and surrounding the site of injury, which contributes to long-lasting functional deficits [1].

Rho kinase (including ROCK₁ and ROCK₂) is one of the AGC families of serine-threonine kinases [2]. Rho kinase is a downstream effector of the small GTPase RhoA, which is a major cytoskeleton regulator. The RhoA/Rho Kinase signaling pathway contributes to diverse neuronal functions ranging from cell migration, survival, axonal guidance, to axonal regeneration [3-5]. This pathway has also been shown to play an important role in the pathophysiology of SCI [6,4,7]. For example, upregulation of RhoA was observed after SCI [8]. Rho kinase has also been shown to be involved in cell death and signaling [9]. It not only regulates morphological apoptotic events such as membrane blebbing [10], fragmentation and phagocytosis of apoptotic cells [11-13], but also mediates production of reactive oxygen species and inflammatory cytokines [14]. However, the mechanism by which RhoA/Rho kinase mediates cell death remains unclear.

Phospholipase A₂ (PLA₂) is a family of enzymes that hydrolyze the acyl bond of glycerophospholipids at the sn-2 position to produce free fatty acid and lysophospholipids [15-17]. The metabolic products of PLA₂s play important roles in cell death [18]. Among different PLA₂ isoforms, cytosolic PLA₂ (cPLA₂) participates in mediating inflammation and cytotoxicity [17]. A main product of cPLA₂ is arachidonic acid (AA)[19], which can give rise to eicosanoids that mediate inflammation, necrosis and apoptosis [19,20]. Our prior research has demonstrated significant increases of PLA₂ activity and cPLA₂ expression following SCI [21,22]. cPLA₂ is highly expressed in neurons, axons and glial cells and peaked at day 1 in axons, day 3 in glial cells, and day 7 in neurons after SCI [21]. Activation of cPLA₂ is sufficient to induce spinal cord

neuronal death *in vitro*. Genetic ablation of cPLA₂ reduces cell loss and tissue damage, and improves behavioral recovery after SCI [22].

After contusive spinal cord injury, neurons and glial cells die acutely caused by primary mechanical force and later by multiple injury mechanisms such as inflammation, oxidation and excitotoxicity [23,24]. A previous study showed that apoptosis occurred in neurons in the lesion area between 4 to 24 hours post-injury and reached the peak at 8 hours [25]. The apoptosis in glial cells were found at all stages from 4 hours to 14 days, with a maximum presence in lesion area 24 hours after injury [25]. This study indicates that neuronal and glial cell apoptosis occurred at the lesion site within 1 day after contusive SCI.

In the present study, we sought to determine potential mechanisms of RhoA/Rho kinase-mediated cell death in both *in vitro* and *in vivo* SCI models. We examined the relationship between RhoA/Rho kinase and cPLA₂ activation in which spinal cord neuronal death was induced by a combined insult of TNF- α and glutamate, the two major mediators of damage in the progression of secondary SCI. Then we confirmed the RhoA/Rho kinase modulation on cPLA₂ activation by injecting Y27631, an inhibitor of Rho kinase, into the lesion site of a T10 contusive SCI produced by the Louisville System Injury Apparatus (LISA) device in adult mice.

Materials and Methods

Reagents

TNF- α (Sigma-Aldrich, T5944), L-glutamic acid (Sigma-Aldrich, G1626), CT04 (Cytoskeleton. Inc., Rho inhibitor I), Y27632 (Enzo Life Sciences, ALX-270-333), arachidonyl trifluoromethyl ketone (ATK) (Cayman Chemical, 62120).

Rats and mice

Sprague-Dawley (SD) E13 pregnant rats and C57BL/6J mice (12 weeks, 18-24g) were purchased from Charles River (USA). Rats and mice were housed at Indiana University School

of Medicine Laboratory Animal Resource Center. All surgical and animal handling procedures were performed as approved under the Guide for the Care and Use of Laboratory Animals (National Research Council) and the Guidelines of the Indiana University School of Medicine Institutional Animal Care and Use Committee.

Cell culture and treatments

Rat primary spinal cord neurons were obtained from SD rat embryonic E15 pups according to a previously established protocol [26]. In brief, E15 rat spinal cords were isolated and placed in L15 medium. Meninges were carefully removed and spinal cords were cut into small pieces, dissociated by incubation in 0.05% trypsin/EDTA 15 min at 37°C and triturated every 5 min. The dissociated cells were washed with and triturated in 10% heat-inactivated fetal bovine serum (FBS), 5% heat-inactivate horse serum (HS), 2mM glutamine-DMEM (all from Gibco, USA) and cultured in 10 cm plate for 30 min at 37°C to eliminate glial cells and fibroblasts. The supernatant which contains neurons was collected and seeded on poly-L-lysine coated 48 well plates and incubated in a humidified atmosphere containing 5% CO₂ at 37°C with 10% FBS + 5% HS + 2 mM glutamine DMEM. After 16 hours, medium was replaced with Neurobasal medium with 2% B27 (Gibco), 1% N2 (Gibco) and 2 mM glutamine. On day 3, 5 μM cytosine-β-D-arabinofuranoside (Sigma-Aldrich) was added for 24 hours to inhibit glia cell proliferation. With this culture protocol, a purity of greater than 94% spinal cord neuronal population was obtained on day 7. All experiments were performed between 7-10 days. Hela cells (ATCC, USA) were cultured in 10% FBS-DMEM (Gibco).

Cell death assessment

A non-radioactive cytotoxicity assay (Promega, USA) was used to measure lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. Released LDH

can convert tetrazolium salt into a red formazan product. On day 7 in culture, the medium was replaced by fresh medium and the neurons were treated by TNF- α , glutamate or combined TNF- α and glutamate for 24 hours. In the inhibition groups, the inhibitors, CT04, Y27632 and ATK pretreated neurons at 40 min before the application of TNF- α , glutamate or the combination. Fifty microliters of supernatant were removed for LDH assay following the vendor's instruction. The LDH level was measured by a 96 well plate reader (1420 multilabel counter, PerkinElmer) at 490 nm wavelength.

Propidium iodide (PI)/Hoechst staining was also used as a measurement of cell death. Hoechst 33342 (Sigma-Aldrich) 5 $\mu\text{g/ml}$ was added to the cells at 37°C for 15 min to label all cell nuclei, followed by incubation with 5 $\mu\text{g/ml}$ PI (Sigma-Aldrich) at room temperature for 10 min to stain dead cell nuclei. After staining, the medium was removed and cells were washed with 0.01M PBS, followed by 10 min of 4% PFA for cell fixation. The fixed cells were then washed 3 times with PBS and ready for imaging using an Olympus IX71 inverted fluorescence microscope (Olympus America Inc.). Three wells were assigned as one group. The images of three views per well were taken. The blue stained cells and the red stained cells were counted using ImageJ software (NIH) and the percentage of death cell was calculated.

Immunofluorescence staining

Immunofluorescence staining was performed as previously described [27]. Briefly, spinal cord neurons on coverslips on day 7 were fixed by 4%PFA followed by washing with 0.01M PBS, blocking 1 hour with 5% goat serum-0.3% Triton X-100-PBS, and staining with anti-rabbit β III tubulin(1:1000, Cell Signaling, USA), anti-mouse NeuN (1:100, EMD Millipore, USA), anti-rabbit ROCK₁ (1:100) or anti-rabbit ROCK₂ (1:100, Santa Cruz, USA) [27], anti-mouse cPLA₂ (1:50, Santa Cruz, USA) antibodies at 4°C overnight. The next day, the cells were washed 3 times with PBS. The anti-rabbit FITC (1:200) or anti-mouse rhodamine (1:200) secondary antibodies (ICN Biochemicals, Aurora, OH) were applied 1 hour at room temperature followed by 3 PBS

washes. The coverslips were mounted by Vectashield mounting medium containing DAPI (Vector Laboratory, Inc.). Images were taken with Olympus BX61 fluorescence microscope (Olympus America Inc.) or by phase invert microscope (Olympus CK2, Japan) at 20x, 40x, and 60x magnifications.

Western blot analysis

Western blotting analysis was performed as described previously [26]. Whole cell lysates were prepared with RIPA buffer and protease/phosphatase inhibitors cocktail (Thermo Scientific). Protein concentration was measured with a Bio-Rad protein assay (Bio-Rad). The amount of 60 µg protein was loaded and separated by 12% or 8% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membrane (PVDF) (Li-COR Biosciences). After 1 hour blocking with LI-blocking buffer (LI-COR Biosciences), the membranes were incubated with primary antibodies overnight at 4°C. Rabbit antibodies specific for phospho-cPLA₂ (1:800), RhoA (1:1000), and cleaved-caspase 3 (1:800) were from Cell Signaling Tech. Inc., and ROCK₁ and ROCK₂ (1:800), GAPDH (1:2000) were purchased from Santa Cruz Biotech. Inc. Mouse antibody specific for cPLA₂ (1:100) was from Santa Cruz Biotech, Inc. and β-tubulin antibody (1:2000) was from Sigma-Aldrich. Following incubation, membranes were washed and incubated with a secondary fluorescence conjugated antibodies, IRDye800, IRDye680 anti-rabbit or IRDye800, IRDye680 anti-mouse (1:10000, Rockland Immunochemicals) for 1 hour at room temperature. After removal of secondary antibody solution via subsequent PBS washes, the membranes were scanned using a LI-COR Odyssey infrared scanner. The images were captured and the densitometries were measured and analyzed by Image Studio2.0 software (LICOR).

Measurement of AA release

Arachidonic acid was measured by an AA ELISA kit (Bluegene Biotech, China) according to the manufacturer's instructions. Briefly, 150 μ L fresh 2%B27-1%N2-2mM Glutamine-Neurobasal medium was replaced in 48 well plates with cultured neurons. 2.5 μ M ATK, 5 μ M Y27632 and 4.0 μ g/ml CT04 were applied to the medium for 40 min, followed by TNF- α and glutamate treatment for 16 hours. Next, 100 μ L supernatant was collected for detection of released AA by ELISA. Following the given instructions, the densitometry of the reaction was measured by a 96 well plate reader (1420 multi-label counter, PerkinElmer) on wavelength 450 nm.

RhoA activity Assay

Following the manual for a RhoA activation assay Biochem kit (Cytoskeleton, Inc.), 600 μ g whole cell lysate was incubated with 50 μ g rhotekin-RBD beads at 4°C, 1 hour. The beads were then washed with wash buffer and treated by 20 μ l 2x Laemmli sample buffer (Bio-Rad, CA, USA) then denatured at 95°C for 5 min. The samples were then ready for Western blot assay.

Co-immunoprecipitation assay

The assay was performed using a Universal Magnetic Co-IP kit (Active Motif Inc.) according to manufacturer's instructions. In brief, 500 μ g cell lysate was combined with 5 μ g ROCK₁ or ROCK₂ antibody, and underwent shaking at 4°C for 4 hours. 25 μ l protein G Magnetic Beads was then added in the reaction and incubated for 1 hour at 4°C. Next, the tube with the beads was placed on a magnetic stand to pellet beads. The supernatant was carefully removed and 500 μ l Co-IP/wash buffer was added to wash the beads 4 times. Next, the bead pellet was suspended in 20 μ l of 2xLaemmli sample buffer and heated at 95°C for 5min, the samples were ready for Western blot assay.

T10 contusive spinal cord injury and treatment

Fifteen C57BL/6J mice (12 weeks, 18-24g) were divided into 3 groups: sham with laminectomy only, T10 SCI with saline, and T10 SCI with Y27632, an inhibitor of Rho kinase. The mouse was anesthetized with a mixture of 17.2 mg/ml Ketamine, 0.475 mg/ml Xylazine and 0.238 mg/ml Acepromazine. The spinal cord contusive injury was performed at the 10th thoracic (T10) vertebral level with the LISA device at a displacement of 0.5 mm from the dorsal surface of the spinal cord, and a velocity of 1.00 M/Sec as previously described [28]. A total of 4 microinjections of Y27632 (1 microliter 100 μ M/injection) were made into the spinal cord immediately after the injury in bilateral and rostrocaudal directions according to the following coordination: 1.0 mm rostrocaudally from the injury epicenter, 0.24 mm laterally from the midline and 0.5 mm ventrally from the dorsal cord surface. After the injury and Y27632 injection, the muscles and skin were closed in layers and the animal received intraperitoneal injection of 1 ml saline. After 24 hours, mice were re-anesthetized and perfusion with 0.01M PBS and 1 cm spinal cord segment containing the lesion center was harvested. The protein was isolated and analyzed by Western Blot assay.

Statistical Analysis

One-way ANOVA was used to determine statistical significance between multiple groups and a Student's *t*-test was utilized to determine significant value differences between 2 groups. Data are reported as mean \pm s.e.m. A *p* value < 0.05 was considered statistically significant.

Results

Combined insults of TNF- α and glutamate induced neurotoxicity *in vitro*.

To mimic secondary neuronal injury after the initial spinal cord trauma, we established an *in vitro* spinal neuronal injury model treated with an inflammatory mediator TNF- α or/and an excitatory mediator glutamate. Rat spinal cord neurons at 7 days of culture in our preparation reached a near pure population of spinal cord neurons (Fig.1 a). Using these neurons, we first

investigated the effect of TNF- α on spinal neuronal death. We tested different concentrations of TNF- α from 20 to 200 ng/ml and different treatment time points from 24 to 72 hours. Regardless of the concentration or treatment time point, TNF- α alone did not induce neuronal death (data not shown). We then tested glutamate neurotoxicity at a concentration range between 3 and 200 μ M for 24 hours. We found that 5 μ M glutamate was the minimum concentration sufficient to induce cell death ($p < 0.05$). The glutamate excitotoxicity peaked at 50 μ M, and increasing concentration of glutamate to 100 or 200 μ M did not induce further increasing of cell death (data not shown). Next we combined TNF- α with a sub-lethal dose of 3 μ M glutamate. We found that TNF- α at 50 and 100 ng/ml significantly increased spinal neuronal death by 45% and 51%, respectively. When combined with 5 μ M of glutamate, TNF- α induced additional 27% (50 ng/ml) and 21% (100 ng/ml) neuron death (Fig. 1 b, c). These data indicated that TNF- α potentiated glutamate neurotoxicity on rat spinal cord neurons, which are in agreement with other reports [29,30].

TNF- α and glutamate induced activation of both RhoA/Rho kinase and cPLA₂

To dissect out the mechanism of neurotoxicity induced by TNF- α and glutamate, we examined RhoA/Rho kinase and cPLA₂ activities. The data showed that, following TNF- α and glutamate treatment, the active form of RhoA (RhoA-GTP), which was precipitated by Rhotekin beads, was increased significantly at 5 minutes (Fig. 2 a, c), decreased at 10 and 30 minutes and elevated considerably by 3 hours post-treatment. Meanwhile, Rho kinase (ROCK₁, ROCK₂) and cPLA₂ were activated as well at 10 min and 30 min and remained highly elevated up to 3 hours post-treatment (Fig. 2 b, d). These results indicate that TNF- α and glutamate treatment activated RhoA, Rho kinase and cPLA₂.

Inhibition of RhoA, Rho kinase and cPLA₂ activation reduced spinal cord neuronal death

To investigate whether RhoA, Rho kinase and cPLA₂ are involved in neuronal death, we applied a RhoA inhibitor CT04, a Rho kinase inhibitor Y27632, and a cPLA₂ inhibitor arachidonyl trifluoromethyl ketone (ATK), to spinal cord neurons at 40 min prior to the combined administration of TNF- α and glutamate. We found that with combined TNF- α and glutamate treatment, neurons showed morphological degenerative changes including neurite retraction and soma condensation as compared to the control; such changes, however, were effectively blocked by treatments of ATK, Y27632 or CT04, respectively (Fig. 3 a-e). LDH releasing assay showed that ATK, Y27632 and CT04 significantly decreased cell death by 19%, 18% and 16% ($p < 0.05$) (Fig. 3 f). Likewise, Propidium iodide (PI)/Hoechst staining showed a significant increase in neuronal death after receiving TNF- α and glutamate treatment as compared to the non-treated; such death, however, were significantly reduced by 43%, 52% and 33%, respectively, by treatments of ATK, Y27632 or CT04 (Fig. 3 a-1-e-1, g). These data indicate that RhoA, Rho kinase and cPLA₂ activation contribute to neuronal pathology and death induced by TNF- α and glutamate.

RhoA or Rho kinase inhibition down-regulated cPLA₂ activation and AA release

To investigate whether RhoA or Rho kinase regulated cPLA₂ activation, inhibitors of Rho kinase (Y27632) and RhoA (CT04) were administered and phospho-cPLA₂ was analyzed by Western blot. The data showed that phospho-cPLA₂ significantly decreased by 60% and 66% by these inhibitors, respectively ($p < 0.01$; Fig. 4 a, b). Moreover, the cPLA₂ inhibitor, ATK, also decreased activation of cPLA₂ by 38% ($p < 0.01$; Fig 4 a, b). To confirm these results, we further measured the levels of AA, which is a primary product of cPLA₂. The data showed that inhibiting either Rho kinase or RhoA decreased AA release by 26% and 26%, respectively ($p < 0.01$; Fig. 4 c). Additionally, direct inhibition of cPLA₂ reduced AA release by 30% ($p < 0.01$; Fig. 4 c). These data indicate that RhoA and Rho kinase may regulate cPLA₂ activation.

ROCK₁ and ROCK₂, two isoforms of Rho kinase, co-localized and bound with cPLA₂

Since inhibition of RhoA and Rho kinase down-regulated cPLA₂ activation, we then asked whether Rho kinase had the same distribution as cPLA₂ and whether it could directly interact with cPLA₂. We stained spinal cord neurons with Rho kinase (ROCK₁ or ROCK₂) and cPLA₂ antibodies and immunofluorescent secondary antibodies. The images showed that ROCK₁ or ROCK₂ existed in cytoplasm, the same distribution as cytosolic PLA₂ (cPLA₂) (Fig. 5 a). Next, we used a co-immunoprecipitation assay to address the second question and found that both ROCK₁ and ROCK₂ directly bound with either p-cPLA₂ or cPLA₂ in two cell types, i.e., spinal cord neurons and Hela cells (Fig. 5 b).

Rho kinase inhibitor Y27632 downregulated cPLA₂ expression and activation following T10 contusive SCI in adult mice

Finally, we confirmed Rho kinase inhibition on cPLA₂ expression and activation *in vivo* in a mouse T10 contusive SCI model using a Louisville Injury System Apparatus (LISA) impactor. This model has been used reliably in our previous studies [28]. It produces consistent and reliable injuries due to its precise determination of the “0” point of the spinal dorsal surface by a laser sensor and precise determination of displacement parameters of injury. Immediately after the injury, four injections of 1 µl Y27632 (100µM), were made into the rostral and caudal host spinal cord on both sides close to the lesion epicenter. At 24 hours post-injury, 1 cm of spinal cord segment containing the injury epicenter was harvested and analyzed by Western Blot. The data showed that at 24 hours post-SCI, the expression of Rho kinase and cPLA₂ was significantly increased. In addition, the apoptotic cell death marker cleaved-caspase 3 was also remarkably increased. Notably, Y27632 administration significantly inhibited expression of Rho kinase, cPLA₂, and phospho-cPLA₂. As anticipated, cleaved-caspase 3 was also significantly reduced (Fig. 6A, B). These data indicate that Rho kinase regulates cPLA₂ activation and subsequently apoptotic cell death.

Discussion

During the secondary SCI process, inflammation, glutamate excitotoxicity and free radical-mediated oxidative stress are major events that contribute to cell death [31,32]. Glutamate is a common mediator of excitotoxicity in the CNS disease and trauma [33]. The inflammatory cytokine TNF- α is another important mediator which participates in inflammatory and cell death post-SCI [34,35,24]. Recently, both *in vitro* and *in vivo* studies demonstrated that TNF- α does not induce neuronal death on its own [30,36]; however, it can potentiate glutamate excitotoxicity by inhibiting glutamate uptake [37], and elevating NF- κ B [37,38] and cFOS activation [36]. Our data are consistent with these reports. Regardless of the dose (up to 200ng/ml) or duration of treatment (up to 72 hours), TNF- α did not induce neuronal loss in the present study. However, when combined with a sub-lethal dose of glutamate, TNF- α significantly increased neuronal death. These data indicate that TNF- α and glutamate act synergistically to induce neuronal death in this model.

Previous studies have demonstrated that TNF- α or glutamate can activate RhoA and Rho kinase [39-41]. RhoA is an essential component of the excitotoxicity pathway, and is sufficient to induce the activation of such pathway [42]. Rho kinase also has been shown to be important in the regulation of cell death [9]. Rho kinase-phosphorylated myosin light chain which stimulates actomyosin contractility that controls apoptosis cell membrane blebbing [11], nuclear disintegration [12] and cellular fragmentation [11]. Rho kinase activation also stimulates phosphatase and tensin homologue (PTEN) and inhibits insulin receptor substrate 1 (IRS1) signaling to inactivated Akt which plays an important role in cell survival[43,44]. In addition, ROCK₂ can promote apoptosis by increasing ezrin phosphorylation, which increases Fas, death receptor clustering and expression[45]. Furthermore, Rho kinase mediates inflammatory cell infiltration and cytokine production [46,47], and mediates reactive oxygen species (ROS) production [48]. Our data also demonstrate that RhoA/Rho kinase activation is involved in cell

death and that inhibiting RhoA or Rho kinase activation significantly reduces neuronal cell death induced by TNF- α and glutamate.

cPLA₂ is an 85kDa protein enzyme that preferentially produces arachidonic acid (AA) by hydrolyzing the sn-2 position of glycerophospholipids[49]. Our lab has previously shown that cPLA₂ activation increased as early as 8 hours and peaked at 7 days post-SCI [22,21]. Activation of cPLA₂ by its activator, ceramide-1-phosphate or A23187, is sufficient to induce neuronal death, whereas cPLA₂ inhibition reduces cell loss *in vitro*[22]. Following acute SCI, cPLA₂ inhibition reduces inflammation, cell death, tissue damage and improves functional recovery [22]. TNF- α or glutamate have also been shown to activate cPLA₂ in several non-neuronal cell types [50,51]. Our results demonstrate that cPLA₂ can be activated by combined stimulation of TNF- α and glutamate, and that inhibition of cPLA₂ significantly decreases neuronal death. These results further confirm that cPLA₂ activation can induce neuronal death.

Recent studies indicate that cPLA₂ can be activated by two distinct pathways, one involves Ca²⁺, and another involves multiple kinases. Elevated Ca²⁺ binds with cPLA₂ amino-terminal C2 domain then activates cPLA₂ [52]. Multiple kinases including p42/p44 mitogen-activated protein kinase (ERK_{1/2} MAPKs) [53], p38 MAPK and MNK1-related protein kinases [54,55] phosphorylate cPLA₂ at serine 505 or 727. Other studies showed that N-terminal kinase (JNK) also activates cPLA₂ [56]. After activation, phospho-cPLA₂ translocate from the cytosol to the nuclear envelope, endoplasmic reticulum and Golgi membranes [57,58] and hydrolyzes glycerophospholipids to produce free fatty acids and lysophospholipids [19]. *In vivo* research showed that ERK_{1/2} and phospho-cPLA₂ were highly co-expressed in neurons, degenerated axons and glial cells at 24 hours post-SCI. U0126, an ERK_{1/2} inhibitor decreased ERK_{1/2} activation and subsequently reduced cPLA₂ activation [22]. RhoA is upstream of not only p38, but also ERK_{1/2}. Active RhoA increases ERK_{1/2} and p38 activation and consequently cPLA₂ phosphorylation, mainly by ERK_{1/2} [59]. Since Rho kinase is the main downstream substrate of

RhoA, we hypothesized that Rho kinase regulates cPLA₂ activation which was confirmed by the present study. Importantly, our *in vitro* and *in vivo* results demonstrated, for the first time, that inhibition of RhoA or Rho kinase remarkably down-regulated active phosphorylated cPLA₂. Moreover, the two isoforms of Rho kinase, ROCK₁ and ROCK₂ co-localized and directly bound with cPLA₂ and phospho-cPLA₂. Inhibition of RhoA and Rho kinase significantly reduced AA release supporting the notion that RhoA/Rho kinase regulates cPLA₂ activation. These data collectively indicate that RhoA and Rho kinase directly regulate cPLA₂ activation and subsequently cell death. However whether Rho kinase can directly phosphorylate cPLA₂ remains unclear and needs to be further investigated.

In summary, the current study has revealed a potential mechanism of neuronal cell death induced by TNF- α and glutamate, which is summarized in the schematic diagram of Figure 7. The combined insult of TNF- α and glutamate activates RhoA and Rho kinase and consequently activates cPLA₂. Active cPLA₂ then translocate from the cytosol to the cell and organelle membranes and hydrolyzes glycerophospholipids to produce AA and eicosanoids, and induces caspase activation and cell death. Thus, our study shows, for the first time, the mechanistic link between RhoA/Rho kinase activation, cPLA₂ activation, and cell death.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements:

This work was supported in part by NIH NS059622, NS073636, DOD CDMRP W81XWH-12-1-0562, Merit Review Award I01 BX002356 from the U.S. Department of Veterans Affairs, Craig H Neilsen Foundation 296749, Indiana Spinal Cord and Brain Injury Research Foundation and

Mari Hulman George Endowment Funds (XMX), and by the State of Indiana ISDH, Grant # 13679 (XW).

Author contributions

XW designed, performed experiments, analyzed data and wrote manuscript; CW designed and wrote manuscript; DE, JP performed experiments; XMX designed experiments and wrote the manuscript.

Reference

1. Borgens RB, Liu-Snyder P (2012) Understanding secondary injury. *The Quarterly review of biology* 87 (2):89-127
2. Schofield AV, Bernard O (2013) Rho-associated coiled-coil kinase (ROCK) signaling and disease. *Critical reviews in biochemistry and molecular biology* 48 (4):301-316. doi:10.3109/10409238.2013.786671
3. Schmandke A, Schmandke A, Strittmatter SM (2007) ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. *The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry* 13 (5):454-469. doi:10.1177/1073858407303611
4. Wu X, Xu XM (2016) RhoA/Rho kinase in spinal cord injury. *Neural regeneration research* 11 (1):23-27. doi:10.4103/1673-5374.169601
5. Jing Liu H-yG, Xiao-feng Wang (2015) The role of the Rho/ROCK signaling pathway in inhibiting axonal regeneration in the central nervous system. *Neural regeneration research* 10 (11):1892-1896
6. Forgione N, Fehlings MG (2014) Rho-ROCK Inhibition in the Treatment of Spinal Cord Injury. *World Neurosurg* 82 (3-4):E535-E539. doi:DOI 10.1016/j.wneu.2013.01.009
7. Cao XJ, Feng SQ, Fu CF, Gao K, Guo JS, Guo XD, He XJ, Huang ZW, Li ZH, Liu L, Liu RH, Lu HZ, Mei XF, Ning B, Ning GZ, Qian CH, Qin J, Qu YZ, Saijilafu, Shi B, Sui T, Sun TS, Wang J, Wen JK, Xiao J, Xu B, Xu HD, Yu PP, Zhang ZC, Zhou Y, Zhou YL (2015) Repair, protection and regeneration of spinal cord injury. *Neural regeneration research* 10 (12):1953-1975. doi:10.4103/1673-5374.172314
8. Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. *The Journal of cell biology* 162 (2):233-243. doi:10.1083/jcb.200301080
9. Shi J, Wei L (2007) Rho kinase in the regulation of cell death and survival. *Archivum immunologiae et therapeuticae experimentalis* 55 (2):61-75. doi:10.1007/s00005-007-0009-7
10. Mills JC, Stone NL, Erhardt J, Pittman RN (1998) Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. *Journal of Cell Biology* 140 (3):627-636. doi:DOI 10.1083/jcb.140.3.627
11. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nature cell biology* 3 (4):339-345. doi:10.1038/35070009
12. Croft DR, Coleman ML, Li SX, Robertson D, Sullivan T, Stewart CL, Olson MF (2005) Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. *Journal of Cell Biology* 168 (2):245-255. doi:DOI 10.1083/jcb.200409049

13. Erwig LP, McPhillips KA, Wynes MW, Ivetic A, Ridley AJ, Henson PM (2006) Differential regulation of phagosome maturation in macrophages and dendritic cells mediated by Rho GTPases and ezrin-radixin-moesin (ERM) proteins. *Proceedings of the National Academy of Sciences of the United States of America* 103 (34):12825-12830. doi:10.1073/pnas.0605331103
14. Shiotani S, Shimada M, Suehiro T, Soejima Y, Yosizumi T, Shimokawa H, Maehara Y (2004) Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats. *Transplantation* 78 (3):375-382
15. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. *Journal of lipid research* 45 (2):205-213. doi:10.1194/jlr.R300016-JLR200
16. Liu NK, Xu XM (2010) Phospholipase A2 and its molecular mechanism after spinal cord injury. *Molecular neurobiology* 41 (2-3):197-205. doi:10.1007/s12035-010-8101-0
17. Liu NK, Xu XM (2012) Neuroprotection and its molecular mechanism following spinal cord injury. *Neural regeneration research* 7 (26):2051-2062. doi:10.3969/j.issn.1673-5374.2012.26.007
18. Cummings BS, Mchowat J, Schnellmann RG (2000) Phospholipase A(2)s in cell injury and death. *Journal of Pharmacology and Experimental Therapeutics* 294 (3):793-799
19. Gijon MA, Leslie CC (1999) Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. *Journal of leukocyte biology* 65 (3):330-336
20. Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 19 (1):85-87. doi:10.1096/fj.04-1807fje
21. Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, Shields CB, Xu XM (2006) A novel role of phospholipase A2 in mediating spinal cord secondary injury. *Annals of neurology* 59 (4):606-619. doi:10.1002/ana.20798
22. Liu NK, Deng LX, Zhang YP, Lu QB, Wang XF, Hu JG, Oakes E, Bonventre JV, Shields CB, Xu XM (2014) Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. *Annals of neurology* 75 (5):644-658. doi:10.1002/ana.24134
23. Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS (2012) Inflammation & apoptosis in spinal cord injury. *Indian J Med Res* 135 (3):287-296
24. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC (2002) Cell death in models of spinal cord injury. *Progress in brain research* 137:37-47
25. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu CY, Choi DW (1997) Neuronal and glial apoptosis after traumatic spinal cord injury. *J Neurosci* 17 (14):5395-5406
26. Jiang XY, Fu SL, Nie BM, Li Y, Lin L, Yin L, Wang YX, Lu PH, Xu XM (2006) Methods for isolating highly-enriched embryonic spinal cord neurons: A comparison between enzymatic and mechanical dissociations. *J Neurosci Meth* 158 (1):13-18. doi:10.1016/j.jneumeth.2006.05.014
27. Liu NK, Xu XM (2006) beta-tubulin is a more suitable internal control than beta-actin in Western blot analysis of spinal cord tissues after traumatic injury. *J Neurotraum* 23 (12):1794-1801. doi:DOI 10.1089/neu.2006.23.1794
28. Zhang YP, Burke DA, Shields LBE, Chekmenev SY, Dincman T, Zhang YJ, Zheng YY, Smith RR, Benton RL, DeVries WH, Hu XL, Magnuson DSK, Whittmore SR, Shields CB (2008) Spinal Cord Contusion Based on Precise Vertebral Stabilization and Tissue Displacement Measured by Combined Assessment to Discriminate Small Functional Differences. *J Neurotraum* 25 (10):1227-1240. doi:10.1089/neu.2007.0388
29. Chao CC, Hu SX (1994) Tumor-Necrosis-Factor-Alpha Potentiates Glutamate Neurotoxicity in Human Fetal Brain-Cell Cultures. *Dev Neurosci-Basel* 16 (3-4):172-179. doi:Doi 10.1159/000112104

30. Miller BA, Sun F, Christensen RN, Ferguson AR, Bresnahan JC, Beattie MS (2005) A sublethal dose of TNF alpha potentiates kainate-induced excitotoxicity in optic nerve oligodendrocytes. *Neurochem Res* 30 (6-7):867-875
31. Coughlan AR (1993) Secondary Injury Mechanisms in Acute Spinal-Cord Trauma. *J Small Anim Pract* 34 (3):117-122. doi:DOI 10.1111/j.1748-5827.1993.tb02628.x
32. Park E, Velumian AA, Fehlings MG (2004) The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. *J Neurotrauma* 21 (6):754-774. doi:10.1089/0897715041269641
33. Sattler R, Tymianski M (2001) Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. *Molecular neurobiology* 24 (1-3):107-129. doi:10.1385/MN:24:1-3:107
34. Pineau I, Lacroix S (2007) Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. *The Journal of comparative neurology* 500 (2):267-285. doi:10.1002/cne.21149
35. Ferguson AR, Christensen RN, Gensel JC, Miller BA, Sun F, Beattie EC, Bresnahan JC, Beattie MS (2008) Cell Death after Spinal Cord Injury Is Exacerbated by Rapid TNF alpha-Induced Trafficking of GluR2-Lacking AMPARs to the Plasma Membrane. *J Neurosci* 28 (44):11391-11400. doi:10.1523/Jneurosci.3708-08.2008
36. Hermann GE, Rogers RC, Bresnahan JC, Beattie MS (2001) Tumor necrosis factor-alpha induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. *Neurobiol Dis* 8 (4):590-599. doi:DOI 10.1006/nbdi.2001.0414
37. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. *Brain Res* 1034 (1-2):11-24. doi:10.1016/j.brainres.2004.11.014
38. Tolosa L, Caraballo-Miralles V, Olmos G, Llado J (2011) TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. *Mol Cell Neurosci* 46 (1):176-186. doi:10.1016/j.mcn.2010.09.001
39. Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde YA (2002) Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. *J Neurosci* 22 (3):854-862
40. Hunter I, Cobban HJ, Vandenabeele P, MacEwan DJ, Nixon GF (2003) Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: Role in the Ca²⁺ sensitization of myosin light chain(20) phosphorylation. *Mol Pharmacol* 63 (3):714-721. doi:Doi 10.1124/Mol.63.3.714
41. Mong PY, Petruccio C, Kaufman HL, Wang Q (2008) Activation of rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. *Journal of immunology* 180 (1):550-558
42. Semenova MM, Maki-Hokkonen AM, Cao J, Komarovski V, Forsberg KM, Koistinaho M, Coffey ET, Courtney MJ (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. *Nat Neurosci* 10 (4):436-443. doi:10.1038/nn1869
43. Li Z, Dong XM, Wang ZL, Liu WZ, Deng N, Ding Y, Tang LY, Hla T, Zeng R, Li L, Wu DQ (2005) Regulation of PTEN by Rho small GTPases. *Nature cell biology* 7 (4):399-U342. doi:Doi 10.1038/Ncb1236
44. Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A (2002) Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. *J Biol Chem* 277 (8):6214-6222. doi:DOI 10.1074/jbc.M110508200
45. Piazzolla D, Meissl K, Kucerova L, Rubiolo C, Baccarini M (2005) Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. *Journal of Cell Biology* 171 (6):1013-1022. doi:DOI 10.1083/jcb.200504137
46. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu XG, Feng QP, Halks-Miller M, Mahmoudi M, Schroeder M, Subramanyam B, Tseng JL, Deng GD, Schirm S, Johns A, Kauser K, Dole WP, Light DR (2005)

- Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. *Circulation* 111 (17):2219-2226. doi:10.1161/01.Cir.0000163544.17221.Be
47. Horton JW, Maass DL, Ballard-Croft C (2005) Rho-associated kinase modulates myocardial inflammatory cytokine responses. *Shock* 24 (1):53-58. doi:10.1097/01.shk.0000167109.96000.7f
48. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo - Effect on endothelial NAD(P)H oxidase system. *Circulation research* 93 (8):767-775. doi:10.1161/01.Res.0000096650.91688.28
49. Clark JD, Schievella AR, Nalefski EA, Lin LL (1995) Cytosolic phospholipase A2. *Journal of lipid mediators and cell signalling* 12 (2-3):83-117
50. Wissing D, Mouritzen H, Egeblad M, Poirier GG, Jaattela M (1997) Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. *Proceedings of the National Academy of Sciences of the United States of America* 94 (10):5073-5077
51. Hoeck WG, Ramesha CS, Chang DJ, Fan N, Heller RA (1993) Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. *Proceedings of the National Academy of Sciences of the United States of America* 90 (10):4475-4479
52. Nalefski EA, Sultzman LA, Martin DM, Kriz RW, Towler PS, Knopf JL, Clark JD (1994) Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain. *J Biol Chem* 269 (27):18239-18249
53. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ (1993) Cpla2 Is Phosphorylated and Activated by Map Kinase. *Cell* 72 (2):269-278. doi:10.1016/0092-8674(93)90666-E
54. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D, Ghomashchi F, Yates JR, 3rd, Armstrong CG, Paterson A, Cohen P, Fukunaga R, Hunter T, Kudo I, Watson SP, Gelb MH (2000) Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. *J Biol Chem* 275 (48):37542-37551. doi:10.1074/jbc.M003395200
55. Waterman WH, Molski TF, Huang CK, Adams JL, Sha'afi RI (1996) Tumour necrosis factor-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils. *The Biochemical journal* 319 (Pt 1):17-20
56. Hernandez M, Bayon Y, Sanchez Crespo M, Nieto ML (1999) Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2. *Journal of neurochemistry* 73 (4):1641-1649
57. Hirabayashi T, Kume K, Hirose K, Yokomizo T, Iino M, Itoh H, Shimizu T (1999) Critical duration of intracellular Ca²⁺ response required for continuous translocation and activation of cytosolic phospholipase A(2). *J Biol Chem* 274 (8):5163-5169. doi:10.1074/jbc.274.8.5163
58. Evans JH, Gerber SH, Murray D, Leslie CC (2004) The calcium binding loops of the cytosolic phospholipase A2 C2 domain specify targeting to Golgi and ER in live cells. *Molecular biology of the cell* 15 (1):371-383. doi:10.1091/mbc.E03-05-0338
59. Mariggio S, Bavec A, Natale E, Zizza P, Salmona M, Corda D, Di Girolamo M (2006) G alpha(13) mediates activation of the cytosolic phospholipase A(2)alpha through fine regulation of ERK phosphorylation. *Cell Signal* 18 (12):2200-2208. doi:10.1016/j.cellsig.2006.05.003

Legend

Fig. 1 Establishment of spinal cord neuronal injury model *in vitro*. **(a)** Highly purified spinal cord neurons stained with a neurite marker β III tubulin and neuronal marker NeuN, counterstained with a fluorescent nuclear marker DAPI. **(b)** Bright-field images show spinal cord neurons that received no treatment (control), or treatment for 24 hour with 50 ng/ml TNF- α , 3 μ M glutamate, or a combination of the two. Arrows show the live cells and arrowheads show the dead cells. **(c)** Neuronal death measured by the LDH assay. Values are means \pm s.e.m. (n = 4). $p < 0.01$ versus control. Bar in A & B = 50 μ m.

Fig. 2 TNF- α and glutamate induced activation of RhoA, Rho kinase and cPLA₂. **(a, b)** Western blot analysis showed that the activation of RhoA **(a)**, Rho kinase and cPLA₂ **(b)** were significantly increased. **(c, d)** Densitometric quantification of RhoA, Rho kinase, and cPLA₂ activation. Data were expressed as fold change compared to the control group. Values are means \pm s.e.m. (n = 4). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Fig. 3 Inhibition of RhoA, Rho Kinase, and cPLA₂ decreased neuronal death induced by TNF- α and glutamate. Spinal cord neurons were pretreated with ATK, Y27632, and CT04 at 40 minutes prior to the application of TNF- α and glutamate. After 24 hours, phase contrast images of neurons were taken (top row) and cells were stained by Propidium iodide (PI, red) and Hoechst (blue) (bottom row) in healthy neurons **(a, a1)** or neurons challenged with TNF- α and glutamate **(b-e, b1-e1)**. In the latter condition, cultured were treated with ATK, a cPLA₂ inhibitor **(c, c1)**, Y27632, a ROCK_{1/2} inhibitor **(d, d1)**, and CT04, a RhoA inhibitor **(e, e1)**. Live neurons with clear cell bodies (top row) and blue Hoechst nuclear staining (bottom row) can be clearly seen (red and white arrows, respectively). Dead neurons with degenerating cell bodies (top row) and red PI nuclear staining (bottom row) can also be appreciated (red and white arrowhead).

Quantitative data show cell death in fold change measured with LDH releasing (f), and in percent change measured by the PI⁺ and Hoechst⁺ cells (g). Values are means ± s.e.m. (n = 4), * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Bars = 50 μm .




Fig. 4 RhoA/Rho kinase regulated cPLA₂ activation. (a) The inhibitors of RhoA (CT04), Rho kinase (Y27632), and cPLA₂ (ATK) down-regulated cPLA₂ activation induced by TNF α and glutamate. (b) The quantification data of active cPLA₂ and GAPDH. (c) The release of AA, the main downstream product of cPLA₂, was significantly reduced by ATK, Y27362 and CT04 (ELISA). Values are means ± s.e.m (n = 3). Data are expressed as fold change compared with the control group, ** $p < 0.01$, *** $p < 0.001$.





Fig. 5 Rho kinase (ROCK₁/ROCK₂) was co-localized and bound directly with cPLA₂. (a) The spinal cord neurons were stained with ROCK₁, ROCK₂, and cPLA₂ antibodies and the images were taken at 60x magnification. Both ROCK₁ or ROCK₂ and cPLA₂ localized in cytoplasm. (b) Whole cell lysates of spinal cord neurons and Hela cells were immunoprecipitated with ROCK₁, ROCK₂ antibodies then immunoblotted by phospho-cPLA₂ and cPLA₂ antibodies. The rabbit IgG antibody was used as a negative control. The data showed p-cPLA₂/cPLA₂ bound directly with ROCK₁ or ROCK₂. Bar=10 μm .





Fig. 6 Rho kinase inhibitor, Y27632, downregulated cPLA₂ and phospho-cPLA₂ and reduced apoptosis cell death in mice T10 contusion model. (a) The Rho kinase inhibitor, Y27632, 1 μl of 100 μM was injected in mice T10 spinal cord/site around lesion area immediately after contusion injury. The spinal cords which contained lesion area were isolated post injury 24 hours and



analyzed by Western blot. **(b)** The quantitative data of densitometry. Values are means \pm s.e.m. (n = 5). Data are expressed as fold change compared with the control group, * $p < 0.05$ · ** $p < 0.01$.

Fig. 7 Schematic drawing illustrates the proposed mechanism of RhoA/Rho kinase and cPLA₂ activation following spinal cord injury. The combined TNF- α and glutamate insults activate RhoA/Rho kinase and cPLA₂. The phospho-cPLA₂ re-localizes to cell and organelle membrane to hydrolyze phospholipids to arachidonic acid (AA) and eicosanoids to induce neuronal death. Inhibition of RhoA, ROCK_{1/2}, and cPLA₂ with CT04, Y27632, and ATK reduces cPLA₂ activation and neuronal death.

a**b****c**

a**b****c****d**



a**b****c**